Knipscheer et al.,177 Belay B, Belamarich PF, Tom-Revzon C. The use of statins in pediatrics: knowledge base, limitations, and futue directions. Pediatrics 2007;119(2):370-80. 1996 |
54/18 |
8-16 anos |
Pravastatina: (1) 5 mg/dia, (2) 10 mg/dia, and (3) 20 mg/dia |
Placebo |
12 semanas |
p < 0,05 |
CT, C-LDL, TGs, C-HDL, apo A-I, apo B, Lp(a), C-VLDL, ALT, AST, hormônios |
Stein et al.,2121 Avis HJ, Hutten BA, Gagné C, Langslet G, McCrindle BW, Wiegman A, et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol. 2010;55(11):1121-6. 1999 |
67/65 |
10- 17 anos |
Lovastatina 10 mg/dia por 8 semanas; 20 mg/d por 8 semanas, 40 mg/dia |
Placebo |
48 semanas |
p < 0,05 |
C-LDL, TGs, CT, C-HDL, apo A-I, apo A-II, apo B, Lp(a), volume testicular, ALT, AST, hormônios, crescimento e desenvolvimento |
de Jongh et al.,1111 Clauss SB, Holmes KW, Hopkins P, Stein E, Cho M, Tate A, et al. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Pediatrics. 2005;116(3):682-8. 2002 |
106/69 |
10-17 anos |
Sinvastatina 10 mg/dia por 8 semanas; 20 mg/dia por 8 semanas; 40 mg/dia |
Placebo |
48 semanas |
p < 0,05 |
C-LDL, CT, TGs, C-HDL, apo A-I, apo B, C-VLDL, PCRas, ALT, AST, hormônios |
McCrindle et al.1616 Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in metaanalyses. BMJ. 2003;327(7414):557-60., 2003 |
140/47 |
10-17 anos |
Atorvastatina 10 mg/dia; 20 mg/dia se LDL ≥ 3.4 na semana 4 |
Placebo |
26 semanas |
p < 0,05 |
C-LDL, CT, TGs, C-HDL, apo A-I, apo B, ALT, AST, hormônios |
Wiegman et al.,1818 den Ende A, et al. Short-term efficacy and safety of pravastatin in 72 children with familial hy-percholesterolemia. Pediatr Res. 1996;39(5):867-71. 2004 |
106/108 |
8-18 anos |
Pravastatina 20 mg/dia se <14 anos; 40 mg/dia se ≥ 14 anos |
Placebo |
104 semanas |
p < 0,05 |
C-LDL, TGs, CT, C-HDL, Lp(a), EMI da carótida, crescimento, maturação, nível hormonal, enzimas do fígado e músculos |
Clauss et al.1010 O'Gorman CS, O'Neill M, Conwell L. Considering statins for cholesterol-reduction inchildren if lifest yle and diet changes do not improve their health: a review of the risks and benefits. Vasc Health Risk Manag. 2010;7:1-14., 2005 |
35/19 |
10-17 anos |
Lovastatina 20 mg/dia por 4 semanas; 40 mg/dia |
Placebo |
24 semanas |
p ≤ 0,05 |
C-LDL, TGs, C-HDL, apo A-I, apo B, Lp(a), C-VLDL, ALT, AST, hormônios |
Rodenburg et al.,1919 Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, Büller HR, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA. 2004;292(3):331-7. 2006 |
90/88 |
8-8 anos |
Pravastatina 20 mg/dia se <14 anos; 40 mg/dia se ≥ 14 anos |
Placebo |
104 semanas |
p < 0,05 |
C-LDL, CT, TGs, C-HDL, apo B, Lp(a), C-VLDL, carotid EMI, proteína C-reativva, marcadores LDLox, complexos imunes |
|
intervenção/placebo |
|
|
|
|
|
|
Van der Graaf et al.2222 Stein EA1, Illingworth DR, Kwiterovich PO Jr, Liacouras CA, Siimes MA, Jacobson MS, et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA 1999;281(2):137-44.. 2008 |
126/122 |
10 -17 anos |
Simvastatina: (1) 10 mg/dia, 20 mg/dia, ou 40 mg/dia mais ezetimibe 10 mg/dia ou placebo por 6 semanas; Sinvastatina: (2) 40 mg/dia mais ezetimibe 10 mg/dia ou placebo por 27 semanas; Todos os pacientes receberam tratamento open-label: (3) sinvastatina 10 mg/dia ou 20 mg/dia mais ezetimibe 10 mg/dia por 20 semanas; |
Placebo |
53 semanas |
p < 0.05 |
C-LDL, CT, TGs, C-HDL, apo B |
Avis et al.,2020 Rodenburg J, Vissers MN, Wiegman A, Miller ER, Ridker PM, Witztum JL, et al. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin. J Am Coll Cardiol. 2006;47(9):1803-10. 2010 |
131/46 |
10- 17 anos |
Rosuvastatina: 5 mg/dia, 10 mg/dia, 20mg/dia |
Placebo |
12 semanas |
p < 0.05 |
ALT, AST, CK, HFE, urina, CT, C-LDL, TGs, C-HDL, apo A-I, apoB |
Braamskamp et al.,2727 Ryu SK, Hutten BA, Vissers MN, Wiegman A, Kastelein JJ, Tsimikas S. Lipoprotein-associated phospholipase A2 mass and activity in children with heterozygous familial hypercholesterolemia and unaffected siblings: effect of pravastatin. J Clin Lipidol 2011;5(1):50-6. 2013 |
79/27 |
6 -17 anos |
Pitavastatina: 1 mg/dia, 2 mg/dia, 4 mg/dia |
Placebo |
12 semanas |
p < 0.05 |
CT, C-LDL, C-HDL, TGs, apo A-I, apoB |